Japan's GLP-1 treatment cap and regain

A prospective real-world study from Japan found that weight loss achieved during time-limited GLP-1 receptor agonist treatment was followed by frequent early regain after mandated cessation. Among the participants with post-treatment observations, 21 of 22 regained weight by two months and 10 of 12 had regained weight by six months^[1]. The result is a warning about what happened in this cohort, not proof that every patient will regain weight or that one treatment policy caused the pattern.

The study followed 104 adults with obesity and without type 2 diabetes under Japan's optimal use guideline. Forty-three received semaglutide and 61 received tirzepatide. The programme required a six-month lifestyle phase before medication, then capped reimbursed treatment at 68 weeks for semaglutide 2.4 mg or 72 weeks for tirzepatide before a washout period^[2]. Those policy conditions are central to the readout. This was not a conventional randomized comparison of continuous treatment against withdrawal.

Who the researchers followed

The cohort included 45 people treated as primary obesity patients and 59 receiving treatment after metabolic or bariatric surgery. The authors called the second group the rescue cohort. Both groups met the same insurance eligibility criteria: a body mass index of at least 27 kg/m2 plus obesity-related comorbidities. Researchers recorded body weight every two months, beginning six months before medication and continuing into the post-cessation phase^[1].

During the required lifestyle-only period, the rescue cohort gained a mean 2.28 kg, and 69% gained weight. The primary cohort was approximately stable, with a mean change of -0.65 kg. The between-group comparison had a reported p value of 0.004^[1]. This contrast describes two groups with different treatment histories. It does not establish that lifestyle support is ineffective, because participants were not randomly assigned to those cohorts or to a lifestyle programme versus no programme.

What happened during medication treatment

After medication started, average percentage weight-change trajectories were similar between the primary and rescue cohorts from month four onward. At month six, the reported changes were -11.8% and -10.8%, respectively, with a p value of 0.57. Across the combined cohort, average change reached -16.3% at month 10, -16.1% at month 12 and -15.5% at month 14^[2]. These are observed group means rather than expected outcomes for an individual.

At month 16, the aggregate mean was -16.0%, but only 30 participants contributed to that endpoint and all were receiving semaglutide. The study therefore cannot use that final time point to compare semaglutide with tirzepatide. Nor can the similar primary and rescue trajectories show that the medicines are interchangeable. Treatment was observed under the guideline rather than assigned to create a head-to-head drug test^[1]. Readers looking at either medicine can review the broader semaglutide research summary and tirzepatide evidence summary.

That distinction also matters when reading the percentages beside other obesity-treatment evidence. A result from the semaglutide evidence base cannot be assumed to describe tirzepatide research, and this cohort was not designed to rank them. Safety findings and prescribing conditions need the same separation. The site's semaglutide safety overview and tirzepatide safety overview cover those questions beyond this paper. Here, the relevant observation is the shared treatment pathway under one national reimbursement guideline, followed by a required washout.

The post-cessation result

Regain appeared quickly among the smaller groups with follow-up after treatment ended. By two months, 95% had regained some weight. By six months, 83% had regained weight. When the authors indexed change to the beginning of the lifestyle phase at month -6, the mean moved from -14.4% at month 16 to -7.0% at month 22^[2]. The direction is clear in the reported sample, but the denominators matter: the two-month proportion came from 22 people and the six-month proportion from 12.

The finding supports a focused question about stopping treatment for a chronic condition. It does not answer whether longer treatment would improve the balance of benefit, adverse effects, cost and access. It also does not isolate the effects of stopping medication from changes in follow-up, behaviour or other care after the treatment cap. A policy comparison would need groups managed under different continuation strategies, with longer and more complete follow-up.

What we don't yet know

This was a prospective cohort, not a randomized withdrawal trial. Only 104 people entered the study, while the latest reported treatment and washout points relied on much smaller subsets. The month-16 treatment estimate included semaglutide recipients only. Those features limit conclusions about how often regain occurs across all eligible patients, whether the pattern differs by medicine, and what would have happened with continued treatment^[1].

The paper is still useful because it follows the sequence created by the Japanese guideline: lifestyle pre-treatment, medication under a fixed cap and observation after cessation. Its most defensible message is that substantial average loss during treatment did not remain intact in the small observed washout sample. It should not be converted into instructions to continue, stop or restart a GLP-1 medicine. Those decisions require an individual clinical assessment and the rules that apply where the patient receives care.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.